ABSTRACT
The mechanisms of granulocytopoiesis stimulation with granulocytic CSF (neupogen), added to chemotherapy protocol (adriablastine+taxotere) in patients with stages III-IV breast cancer, were studied. The hemostimulatory effect of granulocytic CSF preparation is based on stimulation of proliferation and differentiation of granulomonocytopoisis precursor cell in the hemopoietic tissue, due to neupogen effects on hemopoietic elements and on the hemopoiesis-inducing microenvironment cells.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Granulocyte Colony-Stimulating Factor/pharmacology , Granulocytes/drug effects , Hematopoiesis/drug effects , Adult , Breast Neoplasms/blood , Breast Neoplasms/pathology , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Docetaxel , Doxorubicin/administration & dosage , Female , Filgrastim , Granulocyte Colony-Stimulating Factor/administration & dosage , Granulocytes/pathology , Granulocytes/physiology , Humans , Middle Aged , Recombinant Proteins , Taxoids/administration & dosage , Treatment Outcome , Up-Regulation/drug effectsABSTRACT
We studied toxic effects of various schemes of cytostatic treatment on central and peripheral pools of hemopoietic precursor cells in patients with III-IV stages of lung cancer and breast cancer. It was found that erythro- and granulomonocytopoietic precursors are characterized by high resistance to cytostatic treatment compared to morphologically discernible bone marrow elements, which is probably a evolutionary developed property of this cell type aimed at rapid recovery of the hemopoietic tissue.
Subject(s)
Antineoplastic Agents/pharmacology , Breast Neoplasms/drug therapy , Hematopoietic Stem Cells/cytology , Lung Neoplasms/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Marrow Cells/cytology , Bone Marrow Cells/drug effects , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Erythrocytes/cytology , Fluorouracil/therapeutic use , Granulocytes/cytology , Hemoglobins/metabolism , HumansABSTRACT
We compared changes in the granulocytic hemopoietic stem in patients with stage III-IV lung cancer receiving cytostatic therapy by the original CVC and standard CAM schemes. In patients treated with the CVC regimen, the granulocytic hemopoietic stem possessed more potent compensatory capacities.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Leukopoiesis/drug effects , Lung Neoplasms/drug therapy , Lung Neoplasms/physiopathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carboplatin/pharmacology , Carboplatin/therapeutic use , Cyclophosphamide/pharmacology , Cyclophosphamide/therapeutic use , Doxorubicin/pharmacology , Doxorubicin/therapeutic use , Granulocytes/drug effects , Granulocytes/pathology , Humans , Methotrexate/pharmacology , Methotrexate/therapeutic use , Vincristine/pharmacology , Vincristine/therapeutic useABSTRACT
We compared hemopoiesis-stimulating activities of dry pantohematogen and recombinant granulocyte colony-stimulating factor under conditions of cyclophosphamide-induced myelosuppression. These preparations stimulated regeneration of bone marrow granulomonocytopoiesis by various mechanisms.
